Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,226 Million (Mid Cap)
45.00
NA
0.00%
-0.24
5.20%
2.07
Revenue and Profits:
Net Sales:
515 Million
(Quarterly Results - Sep 2025)
Net Profit:
32 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
9.31%
0%
9.31%
6 Months
10.89%
0%
10.89%
1 Year
31.69%
0%
31.69%
2 Years
54.7%
0%
54.7%
3 Years
-0.6%
0%
-0.6%
4 Years
0.26%
0%
0.26%
5 Years
-44.82%
0%
-44.82%
INKON Life Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
21.34%
EBIT Growth (5y)
17.05%
EBIT to Interest (avg)
-6.62
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.78
Tax Ratio
22.16%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.62%
ROE (avg)
3.79%
Valuation key factors
Factor
Value
P/E Ratio
45
Industry P/E
Price to Book Value
2.31
EV to EBIT
39.13
EV to EBITDA
21.51
EV to Capital Employed
2.78
EV to Sales
3.24
PEG Ratio
0.90
Dividend Yield
NA
ROCE (Latest)
7.12%
ROE (Latest)
5.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
514.80
433.90
18.64%
Operating Profit (PBDIT) excl Other Income
43.00
75.40
-42.97%
Interest
6.30
4.10
53.66%
Exceptional Items
0.00
0.00
Consolidate Net Profit
32.50
32.20
0.93%
Operating Profit Margin (Excl OI)
83.60%
110.70%
-2.71%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 18.64% vs 6.09% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 0.93% vs 10.65% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,556.90
1,468.20
6.04%
Operating Profit (PBDIT) excl Other Income
216.20
224.90
-3.87%
Interest
12.90
8.60
50.00%
Exceptional Items
-6.20
-7.60
18.42%
Consolidate Net Profit
116.00
99.20
16.94%
Operating Profit Margin (Excl OI)
74.60%
93.30%
-1.87%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 6.04% vs 27.06% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 16.94% vs 116.65% in Dec 2023
About INKON Life Technology Co., Ltd. 
INKON Life Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






